Cagrilintide: How the Long-Acting Amylin Analogue Works Alongside Semaglutide in CagriSema

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Cagrilintide and CagriSema are investigational compounds that have not yet received regulatory approval for general clinical use. Consult a qualified healthcare professional before making any treatment decisions related to obesity or metabolic health.

What Is Cagrilintide and Why It Matters for Obesity Research

GLP-1 receptor agonists like semaglutide have reshaped pharmacological weight management. However, researchers increasingly recognize that targeting a single hormonal pathway may not be enough for individuals whose bodies resist sustained fat loss. This realization brought cagrilintide into the spotlight.

Cagrilintide is a long-acting amylin analogue—a synthetic peptide engineered to mimic the satiety hormone amylin, but with a dramatically extended duration of action. Developed by Novo Nordisk, it is designed to be paired with semaglutide in a fixed-dose combination called CagriSema.

The logic is simple: Amylin and GLP-1 suppress appetite through different, complementary neuronal circuits. Amylin acts primarily through the brainstem (area postrema) and hypothalamic centers, while GLP-1 engages the gut-brain axis. Combining both in a single injection could produce greater and more durable weight reduction than either alone.

Amylin as a Satiety Hormone: Biological Role

Native amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells after meals. Its role is to signal “fullness” through three main mechanisms:

• Slowing Gastric Emptying: It delays the speed at which food moves from the stomach to the small intestine, prolonging the feeling of fullness.
• Brainstem Suppression: It binds to receptors in the area postrema (a part of the brainstem outside the blood-brain barrier) to deliver a direct “stop eating” message.
• Hypothalamic Modulation: It influences the brain’s “central thermostat” for body weight regulation, potentially affecting the long-term body weight set-point.

Evolution: From Pramlintide to Cagrilintide

The first synthetic amylin analogue, pramlintide (Symlin), was approved in 2005. However, it required injections before every meal (three times daily), making it impractical for long-term obesity management.

Cagrilintide solves this through structural modifications (acylation) that allow it to bind to albumin in the blood, extending its half-life significantly. This allows for once-weekly dosing, transforming the amylin pathway into a viable component for frontline obesity treatment.

Mechanism of Action: Receptor Signaling and Energy Balance

Cagrilintide activates a family of receptors formed by the calcitonin receptor (CTR) complexed with receptor activity-modifying proteins (RAMPs), specifically subtypes AMY1, AMY2, and AMY3.

• The Area Postrema: Activation here triggers acute “meal-terminating” signals.
• The Hypothalamus: Activation here influences the signals that maintain energy balance over months. Researchers hypothesize that sustained activation might gradually shift the body’s weight “set-point” downward, preventing the metabolic slowdown that usually follows weight loss.

CagriSema: The Dual Hormone Strategy

CagriSema combines cagrilintide and semaglutide into a single once-weekly injection. This “dual hormone co-agonist” strategy is effective because it hits two independent satiety pathways simultaneously.

Comparison Table: Mechanisms

Phase 3 Trials: The REDEFINE Program

The clinical development of CagriSema centers on the REDEFINE program.

Weight Loss Efficacy

In the REDEFINE 1 trial, participants receiving CagriSema achieved a mean body weight reduction of approximately 22.7% at 68 weeks. In comparison, those on semaglutide 2.4 mg alone achieved roughly 15.8%. For a 110 kg individual, this is the difference between losing 17 kg versus 25 kg.

Safety and Cardiovascular Impact

The combination has shown improvements in waist circumference, systolic blood pressure, and lipid profiles. The safety profile is broadly consistent with GLP-1 agonists, with the most common side effects being gastrointestinal (nausea, vomiting, diarrhea). These are generally mild to moderate and occur mostly during the dose-escalation phase.

How CagriSema Differs from Other Therapies

Unlike tirzepatide (Zepbound), which targets two incretin pathways (GIP/GLP-1), CagriSema pairs an incretin with an amylin analogue. Because these act through entirely different receptor families, it is theoretically harder for the body to develop “work-around” mechanisms to defend its weight.

Frequently Asked Questions

Is Cagrilintide available today?

No, cagrilintide is not available for general clinical use today. As of April 2026, it remains an investigational drug in Phase 3 trials and has not yet received approval from the FDA or EMA.

What is the difference between Cagrilintide and Pramlintide?

Pramlintide is short-acting (3x daily) and used for diabetes. Cagrilintide is long-acting (1x weekly) and is being developed primarily for obesity.

Can Cagrilintide be used without Semaglutide?

While it has been studied as a monotherapy (showing ~10.8% weight loss in Phase 2), its primary clinical path is the combination with semaglutide, as the dual-peptide approach is significantly more potent.

When to consult a specialist:

If you are looking for weight management options, speak with an endocrinologist about currently approved therapies. CagriSema is currently only accessible through clinical trials (REDEFINE program). Self-treating with unapproved investigational compounds carries significant risk.